InvestorsHub Logo
Followers 33
Posts 2859
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Saturday, 05/15/2021 1:33:24 PM

Saturday, May 15, 2021 1:33:24 PM

Post# of 489
The company has shown that an 'armed' OV boosts the efficacy of its CAR-T therapy (preclinical). The study assessed the effect of BLUE's anti-EGFR CAR-T cells in combo with OVs development by PsiOxus Therapeutics https://psioxus.com/wp-content/uploads/2021/04/AACR2021_Poster_Mar2021.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News